The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.